Open AccessFavorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients
Author(s) -
Ruben J. Colman,
Andrea Portocarrero-Castillo,
Deepika L. Chona,
Jennifer Hellmann,
Phillip Minar,
Michael J. Rosen
Publication year - 2020
Publication title -
inflammatory bowel diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.932
H-Index - 146
eISSN - 1536-4844
pISSN - 1078-0998
DOI - 10.1093/ibd/izaa108
Subject(s) - medicine , adalimumab , infliximab , tumor necrosis factor alpha , gastroenterology , drug , inflammatory bowel disease , thiopurine methyltransferase , surgery , pharmacology , disease
Anti-drug antibodies (ADAs) to anti-tumor necrosis factor alpha (anti-TNF) drugs are associated with increased drug clearance and loss of response. We aimed to assess the effectiveness of starting an immunomodulator (IM) drug in patients with newly detected ADAs on anti-TNF monotherapy.